Gentium S.p.a. Receivables Turnover Ratio (GENT), from the fourth quarter 2013 to the fourth quarter 2012 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Gentium S.p.a.  (GENT)
 

Gentium S.p.a. Accounts Receivables Turnover Ratio from the fourth quarter 2013 to the fourth quarter 2012

Quarterly Results, Trends, Rankings, Statistics


Gentium S.p.a.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2013 to a ratio of 8.16, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the fourth quarter 2013. Average receivable collection period, for the Gentium S.p.a. in Dec 31 2013 quarter, has decreased to 45 days, compared to 50 days, in the 0 quarter.

If we take a look into Healthcare sector 197 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2013 from 0 to 2390.

What is Receivable Turnover Ratio?
What is Gentium S.p.a. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GENT Receivables Turnover Ratio (Dec 31 2013)
IV. Quarter		 0
III. Quarter		 (Jun 30 2013)
II. Quarter		 0
I. Quarter		 (Dec 31 2012)
FY
Y / Y Receivable Change 96.15 % -15.68 % 18.74 % 19.66 % -
Y / Y Revenue Change 52.64 % - -59.82 % - -
Receivable Turnover Ratio (TTM) 8.16 7.23 8.42 11.67 13.57
GENT's Total Ranking # 2390 # 0 # 0 # 0 # 0
Accounts Receivable average collection period days 45 50 43 31 27
Seq. Receivable Change 102.13 % -21.97 % 28.15 % -2.96 % -13.11 %
Seq. Revenue Change - - - - 241.77 %


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 198
Overall Market # 2390

Receivable Turnover Ratio Statistics
High Average Low
0.99 0.81 0.63
(Dec 31 2012)   (Dec 31 2013)





GENT Company Profile • Back to GENT Efficiency Comparisons • Compare GENT Receivables Turnover Ratio to its Competitors

Financial Statements
Gentium S.p.a.'s Accounts Receivable $ 13 Millions Visit GENT's Balance sheet
Gentium S.p.a.'s Sales TTM $ 70 Millions Visit GENT's Income Statement
Sources of GENT's Revenues Visit GENT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GENT's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GENT's Growth Rates GENT's Roa GENT's Inventory Turnover Ratio GENT's Dividend Comparisons
GENT's Profitability Ratios GENT's Roi GENT's Asset Turnover Ratio GENT's Dividend Growth
GENT's Valuation Ratios GENT's Roe GENT's Financial Strength Ratios GENT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2013, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2013 Receivable at quarter ending Dec 31 2013
Fonar Corporation  14.11 $ 69.647  Millions$ 4.937  Millions
Curis Inc   14.08 $ 15.002  Millions$ 1.065  Millions
Correvio Pharma Corp   13.88 $ 4.511  Millions$ 0.325  Millions
Procyon Corporation  13.88 $ 2.969  Millions$ 0.214  Millions
Therapeutic Solutions International Inc   13.64 $ 0.312  Millions$ 0.023  Millions
Panbela Therapeutics Inc   13.61 $ 0.974  Millions$ 0.072  Millions
Ethema Health Corporation   13.37 $ 5.962  Millions$ 0.446  Millions
Davita Inc   13.25 $ 19,484.153  Millions$ 1,471.052  Millions
Cytocore Inc  12.93 $ 5.303  Millions$ 0.410  Millions
Lifeloc Technologies Inc   12.90 $ 8.426  Millions$ 0.653  Millions
Arena Pharmaceuticals Inc   12.74 $ 81.394  Millions$ 6.390  Millions
Acorda Therapeutics Inc   12.68 $ 336.430  Millions$ 26.531  Millions
Aeon Global Health Corp.  12.68 $ 1.461  Millions$ 0.115  Millions
Cyclo Therapeutics Inc   12.60 $ 1.693  Millions$ 0.134  Millions
Cadence Pharmaceuticals Inc  12.55 $ 112.556  Millions$ 8.970  Millions
Statera Biopharma Inc fka Cytocom Inc   12.52 $ 8.488  Millions$ 0.678  Millions
Imunon Inc   12.36 $ 0.500  Millions$ 0.040  Millions
Lisata Therapeutics Inc   12.11 $ 14.668  Millions$ 1.211  Millions
Repligen Corp  11.76 $ 68.169  Millions$ 5.798  Millions
Rockwell Medical inc   11.74 $ 52.380  Millions$ 4.460  Millions
American Caresource Holdings, Inc.  11.73 $ 26.751  Millions$ 2.280  Millions
Aspira Women s Health inc   11.73 $ 2.577  Millions$ 0.220  Millions
Asensus Surgical Inc   11.54 $ 1.431  Millions$ 0.124  Millions
Cytosorbents Corporation  11.46 $ 2.423  Millions$ 0.211  Millions
Incyte Corporation  11.44 $ 354.947  Millions$ 31.033  Millions
Novavax inc   11.41 $ 20.914  Millions$ 1.833  Millions
Apyx Medical Corp  11.29 $ 23.660  Millions$ 2.097  Millions
Vivus Inc  11.27 $ 81.082  Millions$ 7.192  Millions
Surmodics Inc   11.18 $ 56.164  Millions$ 5.022  Millions
Biolife Solutions Inc   11.14 $ 11.120  Millions$ 0.998  Millions

Date modified: 2026-10-07T00:41:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.